Source comparison
CJC-1295 no DAC & Ipamorelin for Body Recomposition: Peptide Comparison
Understanding how CJC-1295 no DAC & Ipamorelin for body recomposition compares to alternative growth hormone protocols clarifies when this combination is the appropriate research tool versus when other compounds better serve specific endpoints. | Peptide/Proto
This comparison does not assign a generated winner or score.
- Understanding how CJC-1295 no DAC & Ipamorelin for body recomposition compares to alternative growth hormone protocols clarifies when this combination is the appropriate research tool versus when other compounds better serve specific endpoints.
- | Peptide/Protocol | Mechanism of Action | GH Secretion Pattern | Half-Life | Cortisol/Prolactin Elevation | Body Recomposition Suitability | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC + Ipamorelin | Dual pathway: GHRH receptor + ghrelin receptor activation | Extended high-amplitude pulses (90–120 min duration) | CJC: 6–8 days; Ipa: 2 hours | Minimal—Ipamorelin is selective | High—synergistic lipolysis + protein synthesis | Best risk-benefit ratio for prolonged body recomposition protocols; mimics natural pulsatility || CJC-1295 with DAC + GHRP-6 | GHRH analog + non-selective ghrelin mimetic | Sustained elevation with high-amplitude spikes | CJC-DAC: 8+ days; GHRP-6: 2 hours | Moderate—GHRP-6 elevates cortisol and prolactin | Moderate—anabolic effects offset by catabolic cortisol | Higher GH output but cortisol elevation compromises fat loss; better for pure mass gain || MK 677 (Ibutamoren) oral | Oral ghrelin mimetic (non-peptide) | Sustained elevation (no pulsatility) |
- The bottom line: CJC-1295 no DAC & Ipamorelin for body recomposition offers the best balance of efficacy, safety, and practicality for sustained metabolic remodeling. It preserves endogenous GH production (critical for long-term hormonal health), avoids the appetite surge that sabotages caloric deficits, and requires only 3–4 injections weekly rather than daily administration.